GCP
TARA icon

GSA Capital Partners’s Protara Therapeutics TARA Stock Holding History

GSA Capital Partners’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-52,332
Closed -$279K – 2144
2025
Q4 		$279K Sell
52,332
-49,156
-48% -$273K 0.02% 1212
2025
Q3 		$441K Buy
101,488
+8,375
+9% +$27.1K 0.04% 937
2025
Q2 		$282K Buy
93,113
+38,256
+70% +$132K 0.02% 1296
2025
Q1 		$234K Buy
54,857
+19,310
+54% +$86.3K 0.02% 1312
2024
Q4 		$188K Buy
+35,547
New +$115K 0.01% 1431

Other funds holding TARA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

GSA Capital Partners's TARA Position: Q1 2026 in Review

GSA Capital Partners sold out of Protara Therapeutics (TARA) in Q1 2026, closing a stake of 52,332 shares — an estimated $279K sold.

GSA Capital Partners first reported a position in TARA in Q4 2024 and held it in 5 quarters. The position peaked at $441K in Q3 2025. 114 funds tracked by Wall St. Rank hold TARA as of Q1 2026.

  • GSA Capital Partners reported no remaining Protara Therapeutics position as of Q1 2026 after selling out during the quarter.
  • GSA Capital Partners sold 52,332 Protara Therapeutics shares in Q1 2026, an estimated $279K.
  • GSA Capital Partners first reported a position in Protara Therapeutics in Q4 2024 and held it in 5 quarters.
  • GSA Capital Partners's Protara Therapeutics position peaked at $441K in Q3 2025.
  • 114 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.